Mirum Pharmaceuticals, Inc. (MIRM) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases affecting children and adults. The company commercializes three approved medicines: LIVMARLI (maralixibat) for cholestatic pruritus in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC); Cholbam (cholic acid) for bile acid synthesis disorders; and Chenodal (chenodiol) for radiolucent gallstones and cerebrotendinous xanthomatosis (CTX). The company operates as a single segment and is currently a large accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $77,875 | $37,497 | $147,097 | $69,095 |
| Net Loss | $(24,638) | $(74,038) | $(49,917) | $(104,168) |
| Operating Cash Flow | N/A | N/A | $11,409 | $(36,105) |
| Cash & Investments | $295,445 | N/A | $295,445 | N/A |
| Convertible Notes (Principal) | $316,250 | $316,250 | $316,250 | $316,250 |
| Accumulated Deficit | $(606,156) | N/A | $(606,156) | N/A |
Note: Q2 2023 results included a one-time loss of $49.1 million from the termination of a revenue interest purchase agreement.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 108% year-over-year for the quarter and 113% for the six-month period. This growth was driven by the commercialization of the Bile Acid Medicines (Cholbam and Chenodal) following the August 2023 acquisition of Travere Therapeutics assets, alongside continued growth in Livmarli sales.
- Improved Net Loss: Net loss narrowed significantly to $24.6 million in Q2 2024 from $74.0 million in Q2 2023. The prior year period was heavily impacted by the $49.1 million loss from terminating the revenue interest purchase agreement (RIPA).
- Operating Expenses: Operating expenses increased to $102.1 million in Q2 2024 from $61.8 million in Q2 2023. Increases were attributed to higher royalties, amortization of acquired intangibles, and expanded commercial and R&D activities.
- Positive Operating Cash Flow: For the six months ended June 30, 2024, the company generated $11.4 million in operating cash flow, a reversal from the $36.1 million used in the same period in 2023.
Guidance, Outlook, and Risks
- Liquidity: As of June 30, 2024, the company held $295.4 million in unrestricted cash, cash equivalents, and investments. Management believes this is sufficient to fund operations for at least the next 12 months.
- Clinical Pipeline: The company reported positive interim data for volixibat in the VANTAGE Phase 2b trial for Primary Biliary Cholangitis (PBC), showing statistically significant improvement in pruritus. The company submitted a New Drug Application (NDA) for Chenodal for CTX to the FDA in June 2024.
- Internal Controls: The company disclosed that material weaknesses in internal control over financial reporting identified in the prior year remain unremediated as of June 30, 2024. These relate to inventory valuation and fair value assessments of acquired technology.
- Competition: The company faces competition from generic entrants for Chenodal and Cholbam, as well as competitors developing similar IBAT inhibitors (e.g., Ipsen's odevixibat).
Investor Verification Checklist
- Verify the status of the material weaknesses in internal controls and the timeline for remediation, as this impacts financial reporting reliability.
- Monitor the FDA review timeline and potential approval for the Chenodal NDA for CTX, which is critical for revenue growth in that indication.
- Assess the impact of generic competition on the Bile Acid Medicines portfolio, given the lack of patent protection for these assets.
- Review the volixibat clinical trial progress and potential for future regulatory filings in PSC and PBC.
- Track the company's cash burn rate relative to its $295.4 million cash position to determine the need for future capital raises.